
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, outlines why faster recruitment, local data requirements for registration, and lower costs make APAC attractive for global Phase III programs.
Clinscience, on September 15th signed an investment agreement to acquire 60% of the digital CRO—EXOM Group. Headquartered in Milan, EXOM carries out its activities in the design, supervision, monitoring and management of Clinical Trials based on its own digital eco-system of more than 20 applications unified in the multi-modular platform Genius Suite.
EXOM Group's proprietary Genius Suite system will allow Clinscience to continue its digital transformation and conduct Clinical Trials with a focus on the needs of both Investigators and Patients and ultimately Sponsors.






